Moderna in Quebec: a turning point for life sciences

This enthusiasm is particularly felt within Montréal International, which has supported 12 projects in the city worth $281 million in this sector in 2021, figures twice as high as those observed in 2020. of the brokerage firm CBRE, which indicated in February that its teams had recently “participated in transactions involving hundreds of thousands of square feet intended for the life sciences”.

Thus, Moderna joins the local ecosystem at a key moment, explains Stéphanie Doyle, Director, Business Development, Life Sciences & Health Technologies – Foreign Investments of Montréal International.

“The arrival of Moderna demonstrates the vigor of our ecosystem in life sciences and health technologies. This is a turning point since the new plant could accelerate the growth of the sector by setting up projects that meet urgent needs,” said Ms. Doyle. “By choosing Quebec, Moderna will be able to count on a pool of highly qualified talent that will allow it to advance its major projects. »

Qualified talents for urgent needs

“The talent pool remains a major attraction factor for this type of project. Quebec and Greater Montreal have everything it takes here to develop the next generation of pharmaceutical and biopharmaceutical solutions to meet the most pressing health needs,” explains Stéphane Paquet, President and CEO of Montreal International. “Foreign companies can benefit from a very welcoming, interconnected ecosystem, with a great spirit of collaboration between universities, research institutions and industry. »

With more than 46,000 professionals in Quebec and some 40,000 students in science, technology, engineering and mathematics (STEM) and life sciences programs, the metropolis (which includes 80% of the Quebec ecosystem) offers a game that stands out.

Diversified hubs in the four corners of the metropolis

Furthermore, the LSHT sector in Quebec is well diversified. There are more than 1,000 companies in Quebec that manufacture medical equipment or develop and distribute pharmacological and homeopathic solutions.

In recent years, our artificial intelligence ecosystem has prompted companies such as Roche, Servier, Novartis and Recursion to open research centers in the Quebec metropolis.

LSHT companies are present throughout the territory, particularly within five hubs in Greater Montreal: the West Island of Montreal, the Saint-Laurent borough, Vaudreuil-Soulanges, Longueuil and the City of Laval Biotech. The latter is also the host of the Armand-Frappier Health Biotechnology Center of the INRS, where some thirty research projects related to COVID-19 are carried out.

Thus, with a pool of talent and world-renowned research establishments, the metropolitan region excels in a field of the future that is set to experience accelerated growth in the coming years.

To learn more about Greater Montreal’s investment climate, see our sector profile on life sciences and health technologies.

We want to give thanks to the author of this write-up for this outstanding web content

Moderna in Quebec: a turning point for life sciences

Check out our social media accounts along with other related pages